| Literature DB >> 30332813 |
Yuanyou Li1,2, Xiaowei Zeng3, Yewei Dong4, Cuiying Chen5,6, Cuihong You7,8, Guoxia Tang9, Junliang Chen10, Shuqi Wang11,12.
Abstract
The rabbitfish Siganus canaliculatus is the first marine teleost shown to be able to biosynthesize long-chain polyunsaturated fatty acids (LC-PUFA) from C18 PUFA precursors catalyzed by two fatty acyl desaturases (fad) including Δ4 Fad and Δ6/Δ5 Fad as well as two elongases (Elovl4 and Elovl5). Previously, hepatocyte nuclear factor 4α (Hnf4α) was demonstrated to be predominant in the transcriptional regulation of two fads. To clarify the regulatory mechanisms involved in rabbitfish lipogenesis, the present study focused on the regulatory role of Hnf4α to elovl5 expression and LC-PUFA biosynthesis. Bioinformatics analysis predicted two potential Hnf4α elements in elovl5 promoter, one binding site was confirmed to interact with Hnf4α by gel shift assays. Moreover, overexpression of hnf4α caused a remarkable increase both in elovl5 promoter activity and mRNA contents, while knock-down of hnf4α in S. canaliculatus hepatocyte line (SCHL) resulted in a significant decrease of elovl5 gene expression. Meanwhile, hnf4α overexpression enhanced LC-PUFA biosynthesis in SCHL cell, and intraperitoneal injection to rabbitfish juveniles with Hnf4α agonists (Alverine and Benfluorex) increased the expression of hnf4α, elvol5 and Δ4 fad, coupled with an increased proportion of total LC-PUFA in liver. The results demonstrated that Hnf4α is involved in LC-PUFA biosynthesis by up-regulating the transcription of the elovl5 gene in rabbitfish, which is the first report of Hnf4α as a transcription factor of the elovl5 gene in vertebrates.Entities:
Keywords: Elovl5; Hnf4α; LC-PUFA biosynthesis; Rabbitfish Siganus canaliculatus; promoter; transcription regulation
Mesh:
Substances:
Year: 2018 PMID: 30332813 PMCID: PMC6214118 DOI: 10.3390/ijms19103193
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Structure analysis of the 5′ flanking sequence of S. canaliculatus elovl5 by deletion. Deletion constructs are represented on the left. Non-coding exons are shown by black boxes. The intron is indicated with a black line between the two exons. The sequence is numbered relative to the transcription start site (TSS), which is defined as the first base of the first 5′ non-coding exon. Promoter activity of each construct is represented with normalized value (Firefly luciferase: Renilla luciferase) on the right. Results are means ± SEM (n = 3). Values in each row not sharing a common letter indicate significant difference (analyzed by ANOVA followed by paired t-test; p < 0.05).
Figure 2The promoter structure of rabbitfish elovl5. (A) Alignment for the conserved elements of NF-Y and SRE in elovl5 promoter region. (B) The position of Hnf4α element in rabbitfish elovl5 promoter region, which is relative to the transcription start site (TSS, +1). The bases with black background refer to Hnf4α-1, TSS, and Hnf4α-2, respectively. The bases underlined are downstream sequence of TSS.
Hnf4α binding sites predicted using online software and site-directed mutation sites.
| TF | Software | Position | Predicted Site | Mutation Site |
|---|---|---|---|---|
| Hnf4α-1 | Comparison | +70 ~ +88 | ACCC | ACACTTTGTACT→× |
| Hnf4α-2 | TF binding ® | −84 ~ −64 | TGCAG | GGCAATGGGCC→× |
The position of each element is numbered relative to the presumed TSS. The bases underlined are the mutation sites for site-directed mutant, “×” denotes deletion.
Figure 3Effects of S. canaliculatus hnf4α over-expression on activity of elovl5 promoter deletion mutants and site-directed mutation in HEK 293T cells. The elovl5 promoter deletion mutants, site-directed mutants and negative control were co-transfected with the overexpression plasmid pcDNA3.1-Hnf4α, while the control group was transfected with the empty vector pcDNA3.1. The negative control pGL4.10 is an empty vector with no promoter sequence upstream the reporter gene. Each plasmid complex was transfected in triplicate in three independent experiments. Significant differences compared with the corresponding control group were analyzed using Student’s t-test; with * denoting p < 0.05.
Figure 4The electrophoretic mobility shift assay (EMSA) of elovl5 probe with Siganus canaliculatus hepatocytes nuclear proteins. Each lane is represented as: Lane 1 (no proteins, 5′ biotin labeled probe), lane 2 (hepatocyte nucleoprotein, 5′ biotin labeled free probe), lane 3 (hepatocyte nucleoprotein, unlabeled competitor probe, 5′ biotin labeled free probe), lane 4 (hepatocyte nucleoprotein, 5′ biotin labeled probe, Hnf4α antibody). Band A is gel shift of DNA-protein complexes. Band B is the free probe. Band C is supershift of DNA-protein-antibody complexes. “+” means that the corresponding material in the row has been added, and “−” means that the material is not added.
Figure 5Q-PCR analysis of hnf4α and elovl5 gene expression level in SCHL cells transfected with hnf4α mRNA or control. The Relative expression of hnf4α and elovl5 were analyzed by qPCR and normalized to 18S rRNA expression using the by 2−ΔΔ method. Results are means ± SEM (n = 3). Significant difference compared with the control group was analyzed using Student’s t-test; with * denoting p < 0.05.
The main fatty acids composition of SCHL cells in over-expressing hnf4α group and control group (% area).
| Main Fatty Acids | Groups | |
|---|---|---|
| Control | Overexpression of | |
| 14:0 | 1.37 ± 0.11 | 1.26 ± 0.01 |
| 16:0 | 14.49 ± 0.21 | 14.54 ± 0.06 |
| 18:0 | 15.28 ± 0.40 | 14.89 ± 0.06 |
| 24:0 | 0.71 ± 0.04 | 0.75 ± 0.01 |
| 18:1n-9 | 21.39 ± 0.56 | 22.03 ± 0.17 |
| 24:1 | 1.23 ± 0.03 | 1.16 ± 0.17 |
| 18:2n-6 | 2.69 ± 0.06 | 2.79 ± 0.03 |
| 18:3n-6 | 0.58 ± 0.06 | 0.60 ± 0.04 |
| 20:2n-6 | 1.08 ± 0.06 a | 1.44 ± 0.05 b |
| 20:4n-6 (ARA) | 0.25 ± 0.02 | 0.35 ± 0.02 |
| 18:3n-3 | 2.41 ± 0.07 | 2.45 ± 0.04 |
| 18:4n-3 | 0.44 ± 0.02 | 0.52 ± 0.03 |
| 20:3n-3 | 4.95 ± 0.15 a | 5.33 ± 0.03 b |
| 20:5n-3 (EPA) | 2.97 ± 0.08 a | 3.28 ± 0.01 b |
| 22:5n-3 | 3.70 ± 0.03 a | 3.90 ± 0.01 b |
| 22:6n-3 (DHA) | 15.39 ± 0.43 a | 16.65 ± 0.04 b |
| ΣSFA | 31.73 ± 0.58 | 31.45 ± 0.06 |
| ΣMUFA | 22.81 ± 0.46 | 23.19 ± 0.10 |
| ΣLC-PUFA | 19.30 ± 0.59 a | 20.89 ± 0.04 b |
| 20:2n-6/18:2n-6 | 0.29 ± 0.00 a | 0.35 ± 0.01 b |
| 20:3n-3/18:3n-3 | 0.67 ± 0.00 a | 0.69 ± 0.00 b |
Results are showed as means ± SEM (n = 3). Values in each row with different superscripts indicate significant difference (analyzed by ANOVA followed by paired t-test; p < 0.05).
Figure 6Fatty acid conversion rates in SCHL cells transfected with hnf4α mRNA compared with control. White columns represent the control groups while the black columns are the experiment groups transfected with hnf4α mRNA. Results are means ± SEM (n = 3). Significant differences compared with the control group were analyzed using Student’s t-test; with * denoting p < 0.05.
Figure 7Q-PCR analysis of hnf4α and elovl5 gene expression level in rabbitfish hepatocytes transfected with hnf4α siRNA or control siRNA (NC). The relative expression of hnf4α and elovl5 were analyzed by qPCR and normalized to 18S rRNA expression using the by 2−ΔΔ method. Results are means ± SEM (n = 3). Significant differences compared with the control group were analyzed using Student’s t-test; with * denoting p < 0.05.
Figure 8Q-PCR analysis of hnf4α, elovl5 and ∆4 fad gene expression level in liver of juvenile rabbitfish injected with Hnf4α agonists (Alverine and Benfluorex) or control. The relative expression of hnf4α, elovl5 and ∆4 fad was analyzed by qPCR and normalized to 18S rRNA expression using the by 2−ΔΔCt method. Control 1 was injected with 0.9% NaCl while control 2 was injected with 2.5% DMSO. Results are means ± SEM (n = 6). Significant differences were analyzed by ANOVA followed by Tukey’s multiple comparison test; with * denoting p < 0.05.
Main fatty acids composition in liver of juvenile rabbitfish injected with control solvent or Hnf4α agonists (Alverine and Benfluorex) (mg·kg−1 dry mass).
| Main Fatty Acids | 0.9% NaCl | DMSO | Alverine | Benfluorex |
|---|---|---|---|---|
| 14:0 | 64.57 ± 3.00 | 68.23 ± 6.92 | 63.33 ± 1.75 | 66.74 ± 2.42 |
| 16:0 | 665.83 ± 39.65 | 644.23 ± 66.56 | 644.91 ± 85.87 | 632.51 ± 23.44 |
| 18:0 | 135.08 ± 19.18 | 128.54 ± 5.02 | 129.51 ± 9.24 | 149.43 ± 31.85 |
| 20:0 | 11.36 ± 0.74 | 12.38 ± 0.63 | 13.16 ± 0.87 | 12.71 ± 0.46 |
| 24:0 | 5.47 ± 0.43 | 6.26 ± 1.44 | 6.99 ± 0.22 | 6.88 ± 1.66 |
| 16:1n-7 | 127.47 ± 8.56 | 144.49 ± 17.31 | 139.50 ± 5.31 | 137.02 ± 5.78 |
| 18:1n-9 | 498.35 ± 40.16 | 500.34 ± 18.62 | 540.13 ± 46.47 | 508.29 ± 23.00 |
| 20:1n-9 | 6.40 ± 0.81 | 8.07 ± 0.60 | 8.45 ± 1.71 | 8.22 ± 1.75 |
| 24:1 | 5.06 ± 0.64 | 5.49 ± 0.34 | 5.77 ± 0.08 | 5.04 ± 0.47 |
| 18:2n-6 | 166.67 ± 32.11 | 164.96 ± 17.76 | 189.71 ± 9.42 | 215.96 ± 6.42 |
| 18:3n-6 | 10.79 ± 1.13 | 11.28 ± 1.55 | 12.72 ± 1.47 | 14.36 ± 1.08 |
| 20:2n-6 | 10.95 ± 2.11 a | 11.91 ± 1.29 ab | 14.15 ± 1.29 ab | 18.61 ± 1.44 b |
| 20:4n-6 (ARA) | 5.81 ± 1.14 | 6.92 ± 0.39 | 9.17 ± 0.49 | 9.09 ± 1.10 |
| 22:2n-6 | 5.10 ± 0.74 | 5.66 ± 0.27 | 6.22 ± 0.43 | 6.72 ± 0.78 |
| 18:3n-3 | 56.06 ± 1.57 | 58.94 ± 3.93 | 66.39 ± 2.13 | 53.71 ± 3.11 |
| 18:4n-3 | 8.92 ± 1.44 | 12.38 ± 0.63 | 13.71 ± 0.82 | 11.44 ± 2.14 |
| 20:3n-3 | 20.89 ± 2.08 | 27.69 ± 2.82 | 27.07 ± 1.39 | 24.82 ± 4.33 |
| 20:5n-3 (EPA) | 12.89 ± 2.80 a | 15.72 ± 2.57 ab | 20.24 ± 1.03 ab | 21.74 ± 0.80 b |
| 22:5n-3 | 58.47 ± 14.38 | 64.67 ± 4.52 | 87.41 ± 7.27 | 84.19 ± 11.84 |
| 22:6n-3 (DHA) | 128.85 ± 32.08 a | 150.16 ± 17.21 ab | 228.95 ± 21.00 b | 184.21 ± 12.77 ab |
| ∑SFA | 695.5 ± 50.75 | 741.14 ± 31.12 | 703.99 ± 25.38 | 714.46 ± 54.49 |
| ∑MUFA | 638.70 ± 49.09 | 642.50 ± 35.66 | 688.79 ± 47.88 | 661.95 ± 17.77 |
| ∑LC-PUFA | 236.99 ± 54.82 a | 282.73 ± 20.30 a | 397.02 ± 32.44 b | 349.38 ± 22.93 ab |
Results are means ± SEM (n = 3). Values in each row with different superscripts indicate significant difference (analyzed by ANOVA followed by paired t-test; p < 0.05).
PCR primers sequence and RNAi nucleotide sequence used in this study.
| Subject | Primers | Nucleotide Sequence |
|---|---|---|
| PCR for 5′ flanking sequence cloning | AP1 | 5′-GTAATACGACTCACTATAGGGC-3′ |
| AP2 | 5′-ACTATAGGGCACGCGTGGT-3′ | |
| E5UA0 | 5′-CCAAACACGTCAAAGGCTAGAGAG-3′ | |
| E5UA1 | 5′-GTGAAGTACAAAGTGTGGGTGCAG-3′ | |
| pfu-PCR for deletion mutant construction | E5P0 | 5′-CGG |
| E5P1 | 5′-CGG | |
| E5P2 | 5′-CGG | |
| E5P3 | 5′-CGG | |
| E5P4 | 5′-CGG | |
| SigE5UA1 | 5′-CCG | |
| EMSA for gel shift | BF (5′ biotinlabeled) | 5′-TCTGCACCCACACTTTGTACTTCACCTCG-3′ |
| BR (5′ biotinlabeled) | 5′-CGAGGTGAAGTACAAAGTGTGGGTGCAGA-3′ | |
| UF (5′ unlabeled) | 5′-TCTGCACCCACACTTTGTACTTCACCTCG-3′ | |
| UR (5′ unlabeled) | 5′-CGAGGTGAAGTACAAAGTGTGGGTGCAGA-3′ | |
| RNAi | NC-F | 5′-UUCUCCGAACGUGUCACGUTT-3′ |
| NC-R | 5′-ACGUGACACGUUCGGAGAATT-3′ | |
| siRNA-F | 5′-AGACUGUAAUUAGACGACAUCTT-3′ | |
| siRNA-R | 5′-GAUGUCGUCUAAUUACAGUCUTT-3′ | |
| Site-directed mutant construction | Elovl5-D3-M1-F | 5′-CGGCATCTCTGCACCCTCACCTCGAGGATATC-3′ |
| Elovl5-D3-M1-R | 5′-GATATCCTCGAGGTGAGGGTGCAGAGATGCCG-3′ | |
| Elovl5-D3-M2-F | 5′-TGCCACTCTCCTGCAGGGTCTGCGTGTTCCTC-3′ | |
| Elovl5-D3-M2-R | 5′-GAGGAACACGCAGACCCTGCAGGAGAGTGGCA-3′ | |
| Hnf4α mRNA construction | T7 promoter primer | 5′-TAATACGACTCACTATAGGG-3′ |
| Pa-Hnf4α | 5′-GAAGGAAAAGGCTTCGGAGGGTTGTTA-3′ | |
| Q-PCR detection for target gene expression | QS-Hnf4α | 5′-CCGACTCTACAGAGCATCACCTG-3′ |
| QA-Hnf4α | 5′-TCATTAGCAGAACCTCCGAGAAG-3′ | |
| QS-Elovl5 | 5′-GCACTCACCGTTGTGTATCT-3′ | |
| QA-Elovl5 | 5′-GCAGAGCCAAGCTCATAGAA-3′ | |
| QS-Δ4 Fad | 5′-GAACACCATTTGTTCCCGAG-3′ | |
| QA-Δ4 Fad | 5′-TTCAGTGCCCTGACGACG-3′ | |
| QS-18S rRNA | 5′-CGCCGAGAAGACGATCAAAC-3′ | |
| QA-18S rRNA | 5′-TGATCCTTCCGCAGGTTCAC-3′ |
Restriction sites are underlined: KpnI (GGTACC) and XhoI (CTCGAG).